SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending due to its significant strategic pivot, recently solidified by a long-term data center lease agreement with AMD. The community is buzzing with excitement, viewing this deal as a major validation of Riot's extensive power infrastructure and its potential to become a dominant player in AI and high-performance computing. This move is also fueling discussions about Riot's potential to secure further large-scale deals beyond traditional Bitcoin mining, with many expecting continued upside as the company leverages its substantial power capacity.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is trending following news of Madryn Asset Management acquiring a significant 91% stake, prompting discussions about potential privatization or delisting to reduce costs. This has ignited debate among traders, with bulls anticipating a massive short squeeze due to the extremely low public float, while skeptics warn of a pump-and-dump scenario. The community is actively discussing the implications of this majority ownership on the stock's future, balancing hopes for a continued rally against concerns for potential dilution or a low buyout.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending due to intense anticipation surrounding its upcoming Cohort 4 data readout for Soquelitinib in atopic dermatitis, expected in January. The community is highly optimistic about the novel oral therapy's potential and its broader implications for autoimmune diseases, with much discussion centering on whether the recent cancellation of a major industry conference presentation hints at a significant partnership or buyout alongside positive results.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe Inc. (ADBE) is a major trending topic amidst multiple analyst downgrades and heightened concerns about AI competition, further fueled by Apple's recent entry into the creative software subscription space. The community is deeply divided, debating whether AI will disrupt Adobe's established position or if the current sell-off represents an oversold buying opportunity given its strong fundamentals and cash flow in a broadly weak software sector.

Memecoin on Injective taken over by the community.

Nonja

NONJA is trending as a high-conviction meme coin directly linked to the Injective (INJ) ecosystem, which its dedicated community anticipates will see explosive growth due to strong fundamentals and an undervalued market position. Hailed as the premier meme on Injective, $NONJA is garnering significant attention for its high burned liquidity, resilient community, and potential to deliver leveraged returns as the underlying chain gains momentum.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is attracting significant attention following its strategic partnership with World Liberty Finance, alongside upcoming launches of its Super App and anticipated collaborations with Stellar and Ripple. The community is highly optimistic, emphasizing ZBCN's robust ISO 20022 and MiCA compliance, which positions it as a key player in real-world on-chain payroll and a compelling early investment opportunity among utility tokens.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to robust ANKTIVA sales, showing significant year-over-year revenue growth, alongside a landmark Saudi FDA approval for its use in non-small cell lung cancer and bladder cancer. This global validation, coupled with promising clinical updates across various cancer types, is igniting community excitement around ANKTIVA's "paradigm shift" potential in immunotherapy and driving strong short squeeze dynamics.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is trending following its strategic acquisition of substantial land and power capacity in Texas, signaling a significant push into AI and high-performance computing data centers. This move has sparked community debate, with many envisioning a re-rating as an undervalued AI infrastructure play given its vast power resources. However, skeptics question the lack of immediate AI deals and potential capital expenditure, especially when comparing its progress to other Bitcoin miners also exploring AI ventures.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy (MSTR) is trending due to renewed bullish sentiment surrounding Bitcoin, sparking intense debate among investors regarding Michael Saylor's aggressive strategy of continuously acquiring Bitcoin through equity offerings. The community is actively discussing potential short squeezes and an impending "face melting run up," though some express concerns about dilution impacting its performance relative to Bitcoin. MSTR remains a key proxy for those tracking institutional interest and the broader cryptocurrency market's trajectory.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investor attention shifts to its strategic transformation into a major AI/HPC data center provider, securing long-term contracts with prominent hyperscalers. The community is buzzing about its strong pipeline of potential new deals and solid financial position, anticipating significant growth beyond its Bitcoin mining roots despite short-term market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5% - Here's Why

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 7.5% - Should You Sell...

Celldex Therapeutics SVPs Engage In Heavy Transactions

Key PointsFreddy A. Jimenez directly sold 4,166 shares for a transaction value of $121,210 on Dec. 4, 2025...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat...

Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% Higher - Should You Buy?

Celldex Therapeutics (NASDAQ:CLDX) Shares Up 4.1% - Here's Why...

Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX

Simplify Asset Management Inc. purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the third quarter, according to its most recent Form 13F filing with...

Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9%

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling...

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average - Time to Sell...

Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX

Corient Private Wealth LLC acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities...

Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $24.00 at Barclays

Barclays raised their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the stock an "underweight" rating in a research report on Wednesday...

TFG Asset Management GP Ltd Has $6.43 Million Stake in Celldex Therapeutics, Inc. $CLDX

TFG Asset Management GP Ltd boosted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 21.1% during the 2nd quarter, according to its most recent Form 13F filing with...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News

CLDXCelldex Therapeutics Inc.